Skip to main content

Table 6 The incidence of respiratory symptoms as reported by symptom diary during 7 days following challenge for the safety population

From: The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline

Symptom / beta2agonist use Mannitol Hypertonic Saline
n 627 (%) 636 (%)
Daytime cough 352 (56.9) 365 (58.4)
Wheeze 270 (43.6) 280 (44.8)
Trouble breathing 270 (43.6) 262 (41.9)
Symptoms interfering with activities 172 (27.8) 178 (27.4)
Night time cough 212 (34.2) 236 (37.8)
Beta2 agonist use 319 (51.5) 333 (53.3)
Nebulised beta2 agonist 16 (2.6) 19 (3.0)